文献速递癫痫脑血管病

血管紧张素受体阻滞剂治疗与高血压患者癫痫发病率的关联

Association Between Angiotensin Receptor Blocker Therapy and Incidence of Epilepsy in Patients With Hypertension.
PubMed 文献 · JAMA Neurol · 2022-01-01

这项队列研究利用德国1274家全科诊所2010年1月至2020年12月的数据,纳入168612例高血压患者并按倾向评分匹配为四类降压药组各42153例。结果显示,与其他降压药类别作为一组相比,血管紧张素受体阻滞剂(ARB)治疗与癫痫发病率显著降低相关(HR 0.77,95%CI 0.65-0.90)。作者认为降压药或可作为高血压患者预防癫痫的新途径。

要点

  • ARB治疗与高血压患者癫痫发病率显著降低相关(HR 0.77,95%CI 0.65-0.90)。
  • ARB组5年癫痫累积发病率为0.99%,低于β受体阻滞剂组的1.47%和钙通道阻滞剂组的1.48%。
  • 作者认为降压药或可作为高血压患者预防癫痫的新途径。

核心结论

  • 在高血压患者中,ARB治疗与癫痫发病率显著降低相关(HR 0.77,95%CI 0.65-0.90)。
  • 作者认为降压药或可作为高血压患者预防癫痫的新途径。

研究设计与样本

  • 队列研究,数据来自德国1274家全科诊所2010年1月至2020年12月的Disease Analyzer数据库(IQVIA)。
  • 纳入18岁及以上、有高血压且至少1次降压药处方的患者,排除索引日期前或后3个月内诊断癫痫者。
  • 共168612例患者进入倾向评分匹配,四类降压药(β受体阻滞剂、ARB、血管紧张素转换酶抑制剂、钙通道阻滞剂)各42153例。

主要发现

  • 患者平均(SD)年龄62.3(13.5)岁,21667例(51.4%)为女性。
  • ARB组5年内癫痫发病率最低:1年0.27%、3年0.63%、5年0.99%。
  • β受体阻滞剂和钙通道阻滞剂组发病率最高:1年均为0.38%;3年β受体阻滞剂0.91%、钙通道阻滞剂0.93%;5年β受体阻滞剂1.47%、钙通道阻滞剂1.48%。
  • 与其他降压药类别作为一组相比,ARB治疗与癫痫发病率显著降低相关(HR 0.77,95%CI 0.65-0.90)。

关键数值与推荐

  • ARB治疗与其他降压药类别作为一组相比,癫痫发病率的HR为0.77(95%CI 0.65-0.90)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Arterial hypertension is associated with an increased incidence of epilepsy. Results from animal studies suggest that angiotensin receptor blocker (ARB) therapy could inhibit epileptic seizures. However, there is a lack of clinical data to support the use of ARB therapy in humans. OBJECTIVE: To assess whether ARB therapy is associated with a decreased incidence of epilepsy in patients with hypertension. DESIGN, SETTING, AND PARTICIPANTS: This cohort study obtained data from the Disease Analyzer database (IQVIA) on patients aged 18 years or older who had hypertension and at least 1 antihypertensive drug prescription. Patients were treated at 1274 general practices between January 2010 and December 2020 in Germany. Data were available for 1 553 875 patients who had been prescribed at least 1 antihypertensive drug. Patients diagnosed with epilepsy before or up to 3 months after the index date were excluded. A total of 168 612 patients were included in propensity score matching. Patients treated with 1 of 4 antihypertensive drug classes (β-blockers, ARBs, angiotensin-converting enzyme inhibitors, and calcium channel blockers [CCBs]) were matched to each other using propensity scores. MAIN OUTCOMES AND MEASURES: The main outcome of the study was the incidence of epilepsy associated with ARB therapy compared with other antihypertensive drug classes. Cox regression models were used to study the association between the incidence of epilepsy and ARBs compared with all other antihypertensive drug classes as a group. RESULTS: The study included a total of 168 612 patients, with 42 153 in each antihypertensive drug class. The mean [SD] age of patients was 62.3 [13.5] years, and 21 667 (51.4%) were women. The incidence of epilepsy within 5 years was lowest among patients treated with ARBs (0.27% at 1 year, 0.63% at 3 years, 0.99% at 5 years) and highest among patients receiving β-blockers and CCBs (0.38% for both β-blockers and CCBs at 1 year; 0.91% for β-blockers and 0.93% for CCBs at 3 years; β-blockers, 1.47%; and CCBs, 1.48% at 5 years). Angiotensin receptor blocker therapy was associated with a significantly decreased incidence of epilepsy (hazard ratio, 0.77; 95% CI, 0.65-0.90) compared with the other drug classes as a group. CONCLUSIONS AND RELEVANCE: In this cohort study of patients with hypertension, ARB therapy was associated with a significantly decreased incidence of epilepsy. The findings suggest antihypertensive drugs could be used as a novel approach for preventing epilepsy in patients with arterial hypertension.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Doege C, Luedde M, Kostev K, et al. Association Between Angiotensin Receptor Blocker Therapy and Incidence of Epilepsy in Patients With Hypertension. JAMA Neurol. 2022. PMID: 36251288. doi:10.1001/jamaneurol.2022.3413

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。